

# SS Microambiente e Biomarcatori dei Tumori Solidi

## Elenco pubblicazioni 20221-2023

- 1 - Chiodoni C, Sangaletti S, Lecchi M, Ciniselli Cm, Cancila V, Tripodi I, Ratti C, Talarico G, Brich S, De Cecco L, Baili P, Truffi M, Sottotetti F, Piccotti F, Tripodo C, Pruneri G, Triulzi T, Corsi F, Cappelletti V, Di Cosimo S, Verderio P, Colombo Mp. A three-gene signature marks the time to locoregional recurrence in luminal-like breast cancer. *Esmo Open* 2023;8:101590
- 2 - Bernardo G, Le Noci V, Di Modica M, Montanari E, Triulzi T, Pupa Sm, Tagliabue E, Sommariva M, Sfondrini L. The Emerging Role of the Microbiota in Breast Cancer Progression. *Cells* 2023;12:
- 3 - Minnai F, Noci S, Mangano N, De Cecco L, Meazza C, Terenziani M, Massimino M, Colombo F. A pilot exome sequencing study suggests that germline variants influence methotrexate-induced toxicities in pediatric patients with localized osteosarcoma. *Pediatric Blood & Cancer* 2023;70:e30501
- 4 - Lo Russo G, Prelaj A, Dolezal J, Beninato T, Agnelli L, Triulzi T, Fabbri A, Lorenzini D, Ferrara R, Brambilla M, Occhipinti M, Mazzeo L, Provenzano L, Spagnoletti A, Viscardi G, Sgambelluri F, Brich S, Miskovic V, Pedrocchi Alg, Trovo' F, Manglaviti S, Giani C, Ambrosini P, Leporati R, Franza A, Mcculloch J, Torelli T, Anichini A, Mortarini R, Trinchieri G, Pruneri G, Torri V, De Braud F, Proto C, Ganzinelli M, Garassino Mc. PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: A multiomics analysis. *Journal For Immunotherapy Of Cancer* 2023;11:
- 5 - Prelaj A, Ganzinelli M, Trovo' F, Roisman Lc, Pedrocchi Alg, Kosta S, Restelli M, Ambrosini E, Brogginini M, Pravettoni G, Monzani D, Nuara A, Amat R, Spathas N, Willis M, Pearson A, Dolezal J, Mazzeo L, Sangaletti S, Correa Am, Aguaron A, Watermann I, Popa C, Raimondi G, Triulzi T, Steurer S, Lo Russo G, Linardou H, Peled N, Filip E, Reck M, Garassino Mc. The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy. *Clinical Lung Cancer* 2023;24:381-387
- 6 - Castagnoli L, Corso S, Franceschini A, Raimondi A, Bellomo Se, Dugo M, Morano F, Prisciandaro M, Brich S, Belfiore A, Vingiani A, Di Bartolomeo M, Pruneri G, Tagliabue E, Giordano S, Pietrantonio F, Pupa Sm. Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer. *Cellular Oncology* 2023;46:661-676
- 7 - Perrone M, Chiodoni C, Lecchi M, Botti L, Bassani B, Piva A, Jachetti E, Milani M, Lecis D, Tagliabue E, Verderio P, Sangaletti S, Colombo Mp. ATF3 Reprograms the Bone Marrow Niche in Response to Early Breast Cancer Transformation. *Cancer Research* 2023;83:117-129
- 8 - Di Cosimo S, Ciniselli Cm, Pizzamiglio S, Cappelletti V, Silvestri M, El Abed S, Izquierdo M, Bajji M, Nuciforo P, Huober J, Cameron D, Chia S, Gomez HI, Iorio Mv, Vingiani A, Pruneri G, Verderio P. End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO. *Frontiers In Oncology* 2023;12:1028825
- 9 - Pietrantonio F, Manca P, Bellomo Se, Corso S, Raimondi A, Berrino E, Morano F, Migliore C, Niger M, Castagnoli L, Pupa Sm, Marchiò C, Di Bartolomeo M, Restuccia E, Lambertini C, Tabernero J, Giordano S. HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial. *Clinical Cancer Research* 2023;29:571-580
- 10 - Bernardo G, Le Noci V, Ottaviano E, De Cecco L, Camisaschi C, Guglielmetti S, Di Modica M, Gargari G, Bianchi F, Indino S, Sartori P, Borghi E, Sommariva M, Tagliabue E, Triulzi T, Sfondrini L. Reduction of *Staphylococcus epidermidis* in the mammary tumor microbiota induces

antitumor immunity and decreases breast cancer aggressiveness. *Cancer Letters* 2023;555:216041

- 11 - Ligorio F, Di Cosimo S, Verderio P, Ciniselli Cm, Pizzamiglio S, Castagnoli L, Dugo M, Galbardi B, Salgado R, Loi S, Michiels S, Triulzi T, Tagliabue E, El Abed S, Izquierdo M, De Azambuja E, Nuciforo P, Huober J, Moscetti L, Janni W, Coccia Portugal Ma, Corsetto Pa, Belfiore A, Lorenzini D, Daidone Mg, Vingiani A, Gianni L, Pupa Sm, Bianchini G, Pruneri G, Vernieri C. Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab. *Jnci-journal Of The National Cancer Institute* 2022;114:1720-1727
- 12 - Fogazzi V, Kapahnke M, Cataldo A, Plantamura I, Tagliabue E, Di Cosimo S, Cosentino G, Iorio Mv. The Role of MicroRNAs in HER2-Positive Breast Cancer: Where We Are and Future Prospective. *Cancers* 2022;14:14215326
- 13 - De Santis F, Romero Cordoba Sl, Castagnoli L, Volpari T, Faraci S, FucÀ G, Tagliabue E, De Braud F, Pupa Sm, Di Nicola M. BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer. *Cellular Oncology* 2022;45:257-274